ORTHYP1
MCID: ORT011
MIFTS: 33

Orthostatic Hypotension 1 (ORTHYP1)

Categories: Eye diseases, Fetal diseases, Genetic diseases, Metabolic diseases, Nephrological diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Orthostatic Hypotension 1

MalaCards integrated aliases for Orthostatic Hypotension 1:

Name: Orthostatic Hypotension 1 58
Norepinephrine Deficiency 58 60 76
Noradrenaline Deficiency 58 60 76
Dopamine Beta-Hydroxylase Deficiency 60 76
Dopamine Beta-Hydroxylase Deficiency, Congenital 58
Orthostatic Hypotension 1, Due to Dbh Deficiency 58
Dbh Deficiency 76
Orthyp1 58

Characteristics:

Orphanet epidemiological data:

60
dopamine beta-hydroxylase deficiency
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Infancy,Neonatal;

OMIM:

58
Inheritance:
autosomal recessive


HPO:

33
orthostatic hypotension 1:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 58 223360
MESH via Orphanet 46 C535600
ICD10 via Orphanet 35 G90.8
UMLS via Orphanet 75 C0342687
Orphanet 60 ORPHA230

Summaries for Orthostatic Hypotension 1

UniProtKB/Swiss-Prot : 76 Dopamine beta-hydroxylase deficiency: Characterized by profound deficits in autonomic and cardiovascular function, but apparently only subtle signs, if any, of central nervous system dysfunction.

MalaCards based summary : Orthostatic Hypotension 1, also known as norepinephrine deficiency, is related to dopamine beta-hydroxylase deficiency and orthostatic hypotension 2. An important gene associated with Orthostatic Hypotension 1 is DBH (Dopamine Beta-Hydroxylase). The drugs Dopamine and Droxidopa have been mentioned in the context of this disorder. Affiliated tissues include eye, and related phenotypes are high palate and ptosis

Description from OMIM: 223360

Related Diseases for Orthostatic Hypotension 1

Diseases in the Primary Orthostatic Hypotension family:

Orthostatic Hypotension 1 Orthostatic Hypotension 2

Diseases related to Orthostatic Hypotension 1 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 dopamine beta-hydroxylase deficiency 12.1
2 orthostatic hypotension 2 11.2
3 dysautonomia 10.2
4 insensitivity to pain, congenital, with anhidrosis 9.7
5 aging 9.7
6 neuropathy, hereditary sensory and autonomic, type v 9.7
7 pain sensitivity quantitative trait locus 1 9.7
8 anhidrosis 9.7
9 primary orthostatic hypotension 9.7
10 pure autonomic failure 9.7

Graphical network of the top 20 diseases related to Orthostatic Hypotension 1:



Diseases related to Orthostatic Hypotension 1

Symptoms & Phenotypes for Orthostatic Hypotension 1

Human phenotypes related to Orthostatic Hypotension 1:

33 (show all 8)
# Description HPO Frequency HPO Source Accession
1 high palate 33 HP:0000218
2 ptosis 33 HP:0000508
3 seizures 33 HP:0001250
4 neonatal hypoglycemia 33 HP:0001998
5 orthostatic hypotension 33 HP:0001278
6 nocturia 33 HP:0000017
7 retrograde ejaculation 33 HP:0012877
8 intermittent hypothermia 33 HP:0005964

Symptoms via clinical synopsis from OMIM:

58
Head And Neck Eyes:
ptosis
delayed eye opening as a neonate (up to 2 weeks)

Head And Neck Mouth:
high-arched palate

Cardiovascular Vascular:
orthostatic hypotension, severe, recurrent
fainting spells

Neurologic Central Nervous System:
seizures may occur during hypotensive episodes

Laboratory Abnormalities:
undetectable norepinephrine (noradrenaline) in plasma, urine, csf
undetectable epinephrine (adrenaline) in plasma, urine, csf
greatly increased dopamine in plasma, urine, csf (approximately 10-fold increase)
increased plasma dihydroxyphenylacetic acid (dopac)
stimulation of sympathetic fibers results in release of dopamine, not norepinephrine
more
Genitourinary Bladder:
nocturia

Head And Neck Nose:
nasal stuffiness

Genitourinary Internal Genitalia Male:
impaired ejaculation due to impaired sympathetic activity
retrograde ejaculation

Metabolic Features:
hypoglycemia, episodic, in infants
hypothermia, episodic, in infants

Clinical features from OMIM:

223360

Drugs & Therapeutics for Orthostatic Hypotension 1

Drugs for Orthostatic Hypotension 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
2
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 23651-95-8 443940
3 Antiparkinson Agents Phase 4,Phase 3,Phase 1,Phase 2
4
Methyldopa Approved Phase 3,Phase 1 555-30-6 38853
5
Metoclopramide Approved, Investigational Phase 3,Phase 1 364-62-5 4168
6
Carbidopa Approved Phase 3,Phase 1,Phase 2 28860-95-9 34359
7
Levodopa Approved Phase 3 59-92-7 6047
8
Mannitol Approved, Investigational Phase 3 69-65-8 6251 453
9 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
10 Sympathomimetics Phase 3,Phase 2,Phase 1,Not Applicable
11 Cardiotonic Agents Phase 3,Phase 2,Phase 1,Not Applicable
12 Neurotransmitter Agents Phase 3,Phase 2,Phase 1,Not Applicable
13 Dopamine Agents Phase 3,Phase 2,Phase 1,Not Applicable
14 Autonomic Agents Phase 3,Phase 2,Phase 1,Not Applicable
15 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
16 Adrenergic Agents Phase 3,Phase 1,Phase 2
17 Dopamine Antagonists Phase 3,Phase 1
18 Dopamine D2 Receptor Antagonists Phase 3,Phase 1
19 Antiemetics Phase 3,Phase 1
20 Gastrointestinal Agents Phase 3,Phase 1
21 Adrenergic Agonists Phase 3,Phase 1,Phase 2
22 Adrenergic alpha-Agonists Phase 3,Phase 1,Phase 2
23 Sympatholytics Phase 3,Phase 1
24 Neurotransmitter Uptake Inhibitors Phase 3,Phase 1
25 Antihypertensive Agents Phase 3,Phase 1
26 Adrenergic alpha-2 Receptor Agonists Phase 3,Phase 1
27 alpha-methyltyrosine Phase 3
28 Atomoxetine Hydrochloride Phase 3
29 Aromatic Amino Acid Decarboxylase Inhibitors Phase 3,Phase 1,Phase 2
30
Norepinephrine Approved Phase 1, Phase 2 51-41-2 439260
31
Entacapone Approved, Investigational Phase 1, Phase 2 130929-57-6 5281081
32 Vasoconstrictor Agents Phase 1, Phase 2
33 Catechol O-Methyltransferase Inhibitors Phase 1, Phase 2
34 Catechol Phase 1, Phase 2
35
Ephedrine Approved Phase 1 299-42-3 9294
36
Atropine Approved, Vet_approved Phase 1 5908-99-6, 51-55-8 174174
37
Cyclopentolate Approved Phase 1 512-15-2 2905
38
Nitric Oxide Approved Phase 1 10102-43-9 145068
39
Tropicamide Approved, Investigational Phase 1 1508-75-4 5593
40
Dipivefrin Approved Phase 1 52365-63-6 3105
41
Pseudoephedrine Approved Phase 1 90-82-4 7028
42
Clonidine Approved Phase 1 4205-90-7 2803
43
Phenylephrine Approved Phase 1 59-42-7 6041
44
Nitroprusside Approved, Investigational Phase 1 15078-28-1 11963622
45
Edrophonium Approved Phase 1 312-48-1, 116-38-1 3202
46
Propranolol Approved, Investigational Phase 1 525-66-6 4946
47
Oxymetazoline Approved, Investigational Phase 1 1491-59-4 4636
48
Isoproterenol Approved, Investigational Phase 1 7683-59-2 3779
49
Yohimbine Approved, Investigational, Vet_approved Phase 1 146-48-5 8969
50 Anti-Arrhythmia Agents Phase 1

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
2 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304) Completed NCT01132326 Phase 3 Droxidopa
3 A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Completed NCT00782340 Phase 3 Placebo;Droxidopa
4 Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00633880 Phase 3 Placebo;Droxidopa
5 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed NCT00738062 Phase 3 Droxidopa;Placebo
6 Treatment of Orthostatic Hypotension Enrolling by invitation NCT00581477 Phase 3 droxidopa;placebo;alpha-methyldopa;carbidopa;metyrosine;levodopa;atomoxetine;metoclopramide
7 A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy Terminated NCT01927055 Phase 3 Droxidopa;Placebo
8 Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans Completed NCT00659230 Phase 2 Nepicastat;Placebo
9 Augmenting Effects of L-DOPS With Carbidopa and Entacapone Terminated NCT00547911 Phase 1, Phase 2 Droxidopa;Carbidopa;Entacapone
10 The Pathophysiology of Orthostatic Hypotension Active, not recruiting NCT00748059 Phase 1 phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine;clonidine,yohimbine,metoclopramide,alpha-methyldopa
11 A Study to Investigate the Genetic Variation of Dopamine Pathway in Patients With Chronic Pain Completed NCT02989792 Not Applicable

Search NIH Clinical Center for Orthostatic Hypotension 1

Genetic Tests for Orthostatic Hypotension 1

Anatomical Context for Orthostatic Hypotension 1

MalaCards organs/tissues related to Orthostatic Hypotension 1:

42
Eye

Publications for Orthostatic Hypotension 1

Articles related to Orthostatic Hypotension 1:

# Title Authors Year
1
Norepinephrine deficiency with normal blood pressure control in congenital insensitivity to pain with anhidrosis. ( 25627679 )
2015
2
Aging-associated formaldehyde-induced norepinephrine deficiency contributes to age-related memory decline. ( 25866202 )
2015
3
Neurogenic orthostatic hypotension: roles of norepinephrine deficiency in its causes, its treatment, and future research directions. ( 26373628 )
2015
4
Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement. ( 25297066 )
2014
5
Norepinephrine deficiency is caused by combined abnormal mRNA processing and defective protein trafficking of dopamine beta-hydroxylase. ( 21209083 )
2011
6
Mutations in the dopamine beta-hydroxylase gene are associated with human norepinephrine deficiency. ( 11857564 )
2002
7
Mice with chronic norepinephrine deficiency resemble amphetamine-sensitized animals. ( 12370425 )
2002
8
Evidence suggesting the role of norepinephrine deficiency in late stages of Parkinson's disease. ( 10410763 )
1999
9
Norepinephrine deficiency and behavioral senescence in aged rats. Transplanted locus ceruleus neurons as an experimental replacement therapy. ( 3474952 )
1987

Variations for Orthostatic Hypotension 1

UniProtKB/Swiss-Prot genetic disease variations for Orthostatic Hypotension 1:

76
# Symbol AA change Variation ID SNP ID
1 DBH p.Val101Met VAR_022758 rs267606760
2 DBH p.Asp114Glu VAR_022759 rs77576840
3 DBH p.Asp345Asn VAR_022760 rs267606761

ClinVar genetic disease variations for Orthostatic Hypotension 1:

6 (show top 50) (show all 168)
# Gene Variation Type Significance SNP ID Assembly Location
1 DBH NM_000787.3(DBH): c.339+2T> C single nucleotide variant Pathogenic rs74853476 GRCh37 Chromosome 9, 136501834: 136501834
2 DBH NM_000787.3(DBH): c.339+2T> C single nucleotide variant Pathogenic rs74853476 GRCh38 Chromosome 9, 133636712: 133636712
3 DBH NM_000787.3(DBH): c.342C> A (p.Asp114Glu) single nucleotide variant Pathogenic rs77576840 GRCh37 Chromosome 9, 136504970: 136504970
4 DBH NM_000787.3(DBH): c.342C> A (p.Asp114Glu) single nucleotide variant Pathogenic rs77576840 GRCh38 Chromosome 9, 133639848: 133639848
5 DBH NM_000787.3(DBH): c.301G> A (p.Val101Met) single nucleotide variant Pathogenic rs267606760 GRCh37 Chromosome 9, 136501794: 136501794
6 DBH NM_000787.3(DBH): c.301G> A (p.Val101Met) single nucleotide variant Pathogenic rs267606760 GRCh38 Chromosome 9, 133636672: 133636672
7 DBH NM_000787.3(DBH): c.1033G> A (p.Asp345Asn) single nucleotide variant Pathogenic rs267606761 GRCh37 Chromosome 9, 136512976: 136512976
8 DBH NM_000787.3(DBH): c.1033G> A (p.Asp345Asn) single nucleotide variant Pathogenic rs267606761 GRCh38 Chromosome 9, 133647854: 133647854
9 DBH NG_008645.1: g.386_387(11_15) NT expansion Benign rs72191426 GRCh37 Chromosome 9, 136496870: 136496871
10 DBH NG_008645.1: g.386_387(11_15) NT expansion Benign rs72191426 GRCh38 Chromosome 9, 133631748: 133631749
11 DBH NM_000787.3(DBH): c.-979T> C single nucleotide variant Benign rs1611115 GRCh37 Chromosome 9, 136500515: 136500515
12 DBH NM_000787.3(DBH): c.-979T> C single nucleotide variant Benign rs1611115 GRCh38 Chromosome 9, 133635393: 133635393
13 DBH NM_000787.3(DBH): c.486A> G (p.Glu162=) single nucleotide variant Benign rs1108580 GRCh38 Chromosome 9, 133639992: 133639992
14 DBH NM_000787.3(DBH): c.486A> G (p.Glu162=) single nucleotide variant Benign rs1108580 GRCh37 Chromosome 9, 136505114: 136505114
15 DBH NM_000787.3(DBH): c.617delA (p.Glu206Glyfs) deletion Pathogenic rs863225244 GRCh37 Chromosome 9, 136507459: 136507459
16 DBH NM_000787.3(DBH): c.617delA (p.Glu206Glyfs) deletion Pathogenic rs863225244 GRCh38 Chromosome 9, 133642337: 133642337
17 DBH NM_000787.3(DBH): c.806G> T (p.Cys269Phe) single nucleotide variant Pathogenic rs863225245 GRCh37 Chromosome 9, 136508596: 136508596
18 DBH NM_000787.3(DBH): c.806G> T (p.Cys269Phe) single nucleotide variant Pathogenic rs863225245 GRCh38 Chromosome 9, 133643474: 133643474
19 DBH NM_000787.3(DBH): c.1085C> A (p.Ala362Glu) single nucleotide variant Pathogenic rs75215331 GRCh37 Chromosome 9, 136513028: 136513028
20 DBH NM_000787.3(DBH): c.1085C> A (p.Ala362Glu) single nucleotide variant Pathogenic rs75215331 GRCh38 Chromosome 9, 133647906: 133647906
21 DBH NM_000787.3(DBH): c.1667A> G (p.Tyr556Cys) single nucleotide variant Pathogenic rs863225246 GRCh38 Chromosome 9, 133657174: 133657174
22 DBH NM_000787.3(DBH): c.1667A> G (p.Tyr556Cys) single nucleotide variant Pathogenic rs863225246 GRCh37 Chromosome 9, 136522296: 136522296
23 DBH 19-bp insertion/deletion indel Benign
24 DBH MspI polymorphic site in intron 9 undetermined variant Benign
25 DBH NM_000787.3(DBH): c.602A> G (p.Asn201Ser) single nucleotide variant Likely benign rs45465204 GRCh38 Chromosome 9, 133642322: 133642322
26 DBH NM_000787.3(DBH): c.602A> G (p.Asn201Ser) single nucleotide variant Likely benign rs45465204 GRCh37 Chromosome 9, 136507444: 136507444
27 DBH NM_000787.3(DBH): c.407T> C (p.Val136Ala) single nucleotide variant Uncertain significance rs886063657 GRCh38 Chromosome 9, 133639913: 133639913
28 DBH NM_000787.3(DBH): c.407T> C (p.Val136Ala) single nucleotide variant Uncertain significance rs886063657 GRCh37 Chromosome 9, 136505035: 136505035
29 DBH NM_000787.3(DBH): c.486+13C> T single nucleotide variant Likely benign rs1611119 GRCh38 Chromosome 9, 133640005: 133640005
30 DBH NM_000787.3(DBH): c.486+13C> T single nucleotide variant Likely benign rs1611119 GRCh37 Chromosome 9, 136505127: 136505127
31 DBH NM_000787.3(DBH): c.631G> A (p.Ala211Thr) single nucleotide variant Likely benign rs5320 GRCh38 Chromosome 9, 133642351: 133642351
32 DBH NM_000787.3(DBH): c.631G> A (p.Ala211Thr) single nucleotide variant Likely benign rs5320 GRCh37 Chromosome 9, 136507473: 136507473
33 DBH NM_000787.3(DBH): c.735C> T (p.His245=) single nucleotide variant Likely benign rs5322 GRCh38 Chromosome 9, 133642455: 133642455
34 DBH NM_000787.3(DBH): c.735C> T (p.His245=) single nucleotide variant Likely benign rs5322 GRCh37 Chromosome 9, 136507577: 136507577
35 DBH NM_000787.3(DBH): c.852C> T (p.Asp284=) single nucleotide variant Uncertain significance rs886063658 GRCh37 Chromosome 9, 136508642: 136508642
36 DBH NM_000787.3(DBH): c.852C> T (p.Asp284=) single nucleotide variant Uncertain significance rs886063658 GRCh38 Chromosome 9, 133643520: 133643520
37 DBH NM_000787.3(DBH): c.1094T> C (p.Met365Thr) single nucleotide variant Uncertain significance rs200103371 GRCh37 Chromosome 9, 136513037: 136513037
38 DBH NM_000787.3(DBH): c.1094T> C (p.Met365Thr) single nucleotide variant Uncertain significance rs200103371 GRCh38 Chromosome 9, 133647915: 133647915
39 DBH NM_000787.3(DBH): c.1139G> A (p.Arg380Gln) single nucleotide variant Uncertain significance rs77984399 GRCh37 Chromosome 9, 136513082: 136513082
40 DBH NM_000787.3(DBH): c.1139G> A (p.Arg380Gln) single nucleotide variant Uncertain significance rs77984399 GRCh38 Chromosome 9, 133647960: 133647960
41 DBH NM_000787.3(DBH): c.1173G> A (p.Thr391=) single nucleotide variant Uncertain significance rs201689325 GRCh37 Chromosome 9, 136513116: 136513116
42 DBH NM_000787.3(DBH): c.1173G> A (p.Thr391=) single nucleotide variant Uncertain significance rs201689325 GRCh38 Chromosome 9, 133647994: 133647994
43 DBH NM_000787.3(DBH): c.1572C> T (p.Asn524=) single nucleotide variant Uncertain significance rs200509113 GRCh38 Chromosome 9, 133657079: 133657079
44 DBH NM_000787.3(DBH): c.1572C> T (p.Asn524=) single nucleotide variant Uncertain significance rs200509113 GRCh37 Chromosome 9, 136522201: 136522201
45 DBH NM_000787.3(DBH): c.1722+4C> T single nucleotide variant Uncertain significance rs45532436 GRCh38 Chromosome 9, 133657233: 133657233
46 DBH NM_000787.3(DBH): c.1722+4C> T single nucleotide variant Uncertain significance rs45532436 GRCh37 Chromosome 9, 136522355: 136522355
47 DBH NM_000787.3(DBH): c.1734C> T (p.Asn578=) single nucleotide variant Conflicting interpretations of pathogenicity rs45446891 GRCh38 Chromosome 9, 133658327: 133658327
48 DBH NM_000787.3(DBH): c.1734C> T (p.Asn578=) single nucleotide variant Conflicting interpretations of pathogenicity rs45446891 GRCh37 Chromosome 9, 136523449: 136523449
49 DBH NM_000787.3(DBH): c.*431C> T single nucleotide variant Uncertain significance rs551208345 GRCh37 Chromosome 9, 136524000: 136524000
50 DBH NM_000787.3(DBH): c.*431C> T single nucleotide variant Uncertain significance rs551208345 GRCh38 Chromosome 9, 133658878: 133658878

Expression for Orthostatic Hypotension 1

Search GEO for disease gene expression data for Orthostatic Hypotension 1.

Pathways for Orthostatic Hypotension 1

GO Terms for Orthostatic Hypotension 1

Sources for Orthostatic Hypotension 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....